What 5-MeO-DMT Is
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is a naturally occurring tryptamine alkaloid found in a wide range of plant species — including seeds of Anadenanthera peregrina and A. colubrina, bark of several Virola species, and roots and leaves of numerous legumes — as well as in the venom of the Sonoran Desert toad (Incilius alvarius, also called Bufo alvarius). It is also produced synthetically. Like N,N-DMT, it is an endogenous compound detectable in mammalian tissues, including the human brain, though its physiological role is poorly understood.
Despite sharing a name suffix with N,N-DMT, the addition of a methoxy group at the 5-position produces profoundly different pharmacology and a categorically different experience. Where N,N-DMT characteristically produces rich visual content, entities, and complex geometric architecture, 5-MeO-DMT typically produces the obliteration of all content — visual, conceptual, personal — into undifferentiated, expansive awareness. It should not be conflated with N,N-DMT. Many people who have extensive experience with psilocybin, LSD, or N,N-DMT find 5-MeO-DMT to be in a different category of intensity entirely.
Sources: Toad Secretion vs. Synthetic
The primary source of 5-MeO-DMT in contemporary Western practice is the dried secretion of Incilius alvarius — the Sonoran Desert toad. The toad's parotoid glands (prominent glands behind the eyes and on the shoulders) produce a secretion containing 5-MeO-DMT alongside bufotenine and other tryptamines at concentrations that make it the most potent naturally occurring source of 5-MeO-DMT known. The secretion is typically collected from living toads, dried, and vaporised. This practice has grown dramatically in recent years, particularly in retreat and ceremonial contexts in Mexico, generating significant conservation concern.
Wild populations of Incilius alvarius in the Sonoran Desert are under documented pressure from the dramatic increase in demand for toad secretion. The toad has a restricted range (Sonoran Desert of Arizona and Mexico), and collection practices in retreat settings often involve significant stress and harm to the animals. Herpetologists and conservationists have raised alarms about population-level impacts. Independent of conservation concerns, the use of stressed wild animals as sacramental vessels raises animal welfare questions that practitioners and seekers should engage with honestly. Synthetic 5-MeO-DMT is chemically identical to the compound in toad secretion, produces the same experience, involves no animal harm, and is the recommended choice from conservation and welfare perspectives. There is no experiential, pharmacological, or spiritual justification for preferring toad-source over synthetic in contemporary practice.
Plant-source 5-MeO-DMT — from Anadenanthera seeds or Virola bark — is used in traditional snuff preparations in South America and is a sustainable alternative for those who prefer natural sources. Yopo snuff (A. peregrina seeds) contains both 5-MeO-DMT and bufotenine and has been used in ceremonial contexts across the Amazon and Caribbean for thousands of years.
History & Cultural Roots
Indigenous use of 5-MeO-DMT-containing plants significantly predates any Western engagement with the compound. Archaeological evidence for snuffed Anadenanthera preparations dates to at least 3000 BCE in the Atacama. The Yanomami, Waorani, and many other Amazonian peoples have used yopo and related snuffs in healing, divination, and ceremonial contexts for millennia. The role of Virola species in shamanic contexts across the Northwest Amazon was documented in detail by Richard Evans Schultes from the 1940s onward.
The Sonoran Desert toad as a psychoactive source is far more recent in documented history — the identification of the toad's secretion as a 5-MeO-DMT source is attributed to a 1983 self-published pamphlet issued under the pseudonym “Albert Most” — the identity of its actual author remains disputed. The practice spread rapidly through psychedelic subcultures in the 1990s and exploded internationally from the 2010s onward, driven partly by the retreat industry in Mexico. Contemporary ceremonial framing of toad secretion as “the medicine of Bufo” or under the name “Sapo” is largely a recent Western and mestizo innovation; the Seri people of Sonora, whose traditional territory overlaps with the toad's range, have explicitly stated that the toad is not part of their ceremonial tradition.
How 5-MeO-DMT Works
5-MeO-DMT is a potent agonist at multiple serotonin receptor subtypes, with particularly high affinity at 5-HT1A and 5-HT2A receptors. Its action at 5-HT1A — an autoreceptor that can inhibit serotonin release — is thought to contribute to the qualitative difference from N,N-DMT: where N,N-DMT's primary action at 5-HT2A produces rich excitatory phenomenology, 5-MeO-DMT's combined 5-HT1A/5-HT2A profile may produce the distinctive blanking-out of content into undifferentiated awareness. Sigma-1 receptor interactions and MAOA substrate activity also contribute to its complex pharmacological profile.
Like N,N-DMT, 5-MeO-DMT is rapidly metabolised by MAO enzymes, producing the characteristic short duration when inhaled. It is also substantially more potent by weight than N,N-DMT — active doses are 3–5 times smaller. When bufotenine is present in the same preparation (as in toad secretion), the combined pharmacology may differ from pure 5-MeO-DMT, though bufotenine itself is not orally active without MAOI and has lower psychoactivity via inhalation at the concentrations typically present.
Effects
The character of the experience
5-MeO-DMT experiences are characteristically described as a complete dissolution of self, world, and all content into an undifferentiated field of awareness. Unlike N,N-DMT, there are typically no entities, no geometric visuals, no structured narrative — the experience often lacks all form. What remains is described variously as: pure consciousness without an object; blinding white light or boundless space; a sense of infinite expansion or merger with everything; and what many people describe as the most profound experience of their lives — and simultaneously the most terrifying or the most peaceful, depending on how the dissolution lands.
The quality of the experience is highly sensitive to set, intention, and the presence and quality of a guide. Complete ego dissolution arrived at with surrender and preparation tends toward awe, love, and a sense of cosmic homecoming. The same dissolution encountered with resistance — fighting the loss of self — tends toward terror, dissociation, and what is sometimes called a “rough ride.” The polarisation between these outcomes is more extreme with 5-MeO-DMT than with most other psychedelics.
Physical effects
Physical effects during the peak are significant: marked increases in heart rate and blood pressure; possible intense breathing changes or hyperventilation; vocalisations (screaming, laughter, crying, or other sounds are not uncommon and should be normalised in advance); trembling; and temporary complete loss of physical coordination. Practitioners recommend supine position with head support throughout the experience. Nausea and purging occur in some people, more commonly with toad secretion than with synthetic preparations.
Duration
Inhaled: onset within seconds; peak 5–15 minutes; return toward baseline by 30–45 minutes; afterglow can persist for hours. Total acute experience is substantially shorter than smoked N,N-DMT in some respects (less content to navigate), but the aftermath often feels longer due to the magnitude of what was encountered.
Reactivations
A distinctive and important feature of 5-MeO-DMT is the prevalence of “reactivations” — spontaneous re-emergence of aspects of the experience hours to days after the session, without further substance use. These can range from pleasant waves of openness and connectedness to frightening re-emergence of dissolution states. Integration support that prepares people for the possibility of reactivations and provides a framework for navigating them is essential to responsible practice.
Dosage Reference
These ranges apply to synthetic 5-MeO-DMT or pure preparations. Toad secretion potency varies; the ranges below are not directly transferable to toad administration without conversion. Start significantly lower than these ranges with unfamiliar material.
| Level | Synthetic (inhaled) | Character |
|---|---|---|
| Threshold | 2–5 mg | Altered awareness, warmth, mild dissolution. Reality remains present. |
| Moderate | 5–10 mg | Significant ego softening; possible partial dissolution. Preparation important. |
| Full / breakthrough | 10–20 mg | Complete ego dissolution typical. Presence of experienced guide strongly recommended. |
The dose-response curve for 5-MeO-DMT is steep and individual sensitivity varies substantially. Working with an experienced guide who can calibrate dose based on observation and prior experience with the individual is strongly recommended, particularly for breakthrough experiences. The difference between a manageable moderate experience and a terrifying overdose can be a few milligrams.
What the Research Shows
Research on 5-MeO-DMT has grown significantly since 2018. Uthaug and colleagues published the first prospective observational study examining 5-MeO-DMT administered in ceremonial contexts (2019), finding significant reductions in depression, anxiety, and PTSD symptoms at four-week follow-up. Barsuglia and colleagues examined 5-MeO-DMT in a residential setting and found comparable improvements in wellbeing and satisfaction with life. Davis and colleagues (2019) published survey research examining retrospective reports of challenging experiences specifically, identifying risk factors and protective factors for difficult outcomes.
Timmermann and colleagues at Imperial College London have led the most methodologically rigorous neuroimaging and psychometric work: their 2023 study using combined EEG-fMRI found that 5-MeO-DMT produces the most globally interconnected brain state yet observed among studied psychedelics, characterised by suppression of the posterior hot zone (associated with conscious content) and expansion of global integration — consistent with the experiential obliteration of content into undifferentiated awareness. A Phase 2 clinical trial examining 5-MeO-DMT for treatment-resistant depression is underway at Imperial. The company Beckley Psytech has progressed a synthetic 5-MeO-DMT formulation (BPL-003) through Phase 2 trials for depression and alcohol use disorder.
Risks & Contraindications
Lithium is a particularly dangerous combination with 5-MeO-DMT — associated with seizures and cardiac events. MAOIs, SSRIs, and stimulants also carry significant risk. View full drug interaction chart →
Cardiac: Blood pressure and heart rate increase significantly during the acute experience. Individuals with cardiovascular disease, hypertension, or significant cardiac risk factors should approach this compound with medical consultation and significant caution.
Serotonin syndrome with MAOIs: This is the most serious pharmacological interaction risk. Combining 5-MeO-DMT with pharmaceutical MAOIs is potentially fatal and represents an absolute contraindication. Syrian rue (Peganum harmala) and ayahuasca-style MAOI plants also present this risk. The harmine and harmaline present in ayahuasca are MAO inhibitors; combining them with 5-MeO-DMT — even sequentially within a short period — can be life-threatening. Practitioners who facilitate both ayahuasca and 5-MeO-DMT in the same retreat context must apply rigorous washout timing.
Personal or family history of psychosis: Absolute contraindication, as with all classic psychedelics.
Psychological unpreparedness: Complete ego dissolution is not a gentle experience. People who have not had significant experience with other psychedelics, who carry significant unprocessed trauma without therapeutic support, or who are not genuinely prepared for the complete disappearance of self should not approach breakthrough doses of 5-MeO-DMT. This is a compound where preparation and guide quality are not optional enhancements — they are essential safety infrastructure.
Reactivations: As described above, spontaneous reactivations are common and can be disorienting or frightening. Integration support must include specific preparation for this possibility.
Physical safety during the experience: Persons must be in a safe supine position; physical coordination is absent during peak effects. Falls and self-injury are possible without appropriate physical support from a sitter.
Legal Status
5-MeO-DMT is a Schedule I substance in the United States, Class A in the UK, and controlled under similar legislation in most Western countries. Several notable exceptions exist: in Mexico, 5-MeO-DMT is not explicitly scheduled (as of 2025), which is a primary reason why the ceremonial retreat industry using this compound is concentrated there. In some jurisdictions, the legal status of toad secretion as a biological preparation distinct from a scheduled chemical creates a regulatory grey area, though this distinction is not consistently recognised by enforcement authorities.
Frequently Asked Questions
The primary psychoactive component of Bufo alvarius toad secretion is 5-MeO-DMT, so in terms of the core pharmacological experience, yes. Toad secretion also contains bufotenine and other compounds not present in pure synthetic 5-MeO-DMT, which some practitioners and researchers believe contribute to a distinctive quality of the experience. However, the core phenomenology and risks are primarily driven by 5-MeO-DMT in both cases. Given serious conservation and animal welfare concerns about toad collection, synthetic 5-MeO-DMT is the preferred choice for harm reduction, conservation, and welfare reasons. The compound is chemically identical.
Vocalisations during 5-MeO-DMT are common and reflect the somatic and emotional intensity of complete ego dissolution. The loss of ordinary self-control is total — the normal suppression of sounds and physical expression dissolves along with everything else. Screaming, sobbing, laughing, and other vocalisations are not signs of pathology or a “bad experience” (though difficult experiences certainly occur); they are common features of the somatic release that often accompanies this magnitude of altered state. People who are informed about this in advance and who understand it as a normal feature of the experience tend to navigate it with greater equanimity than those who encounter it as a surprise.
The 5-MeO-DMT ceremonial scene has grown faster than quality control has. There have been documented deaths associated with 5-MeO-DMT sessions facilitated by untrained practitioners — primarily due to MAOI interactions (combining with ayahuasca or Syrian rue), inadequate screening, and physical mismanagement during the experience. Minimum standards to look for in any facilitator: they work exclusively with synthetic 5-MeO-DMT or clearly traceable plant-source material (not wild-caught toad); they conduct thorough screening including medication review (with specific screening for MAOIs, SSRIs, and cardiovascular medication); they have a protocol for physical management and safety during the session; they offer structured integration support before and after; and they can describe their training and experience specifically, not generically. The 5-MeO-DMT Research Association (5-MeO-DMTRA) has published practitioner guidelines. See our Facilitation page.
In terms of the totality of ego dissolution and the obliteration of ordinary experiential content, 5-MeO-DMT is widely described by those experienced with multiple psychedelics as the most intense — not in the sense of more complex content (ibogaine and high-dose psilocybin produce richer narrative content), but in the sense of complete dissolution into undifferentiated awareness. Potency by weight is extraordinarily high: active doses are in the milligram range, similar to LSD. However, comparisons of “power” between psychedelics are not particularly useful as a guide to which is appropriate for a given person or intention. The experience of ibogaine, ayahuasca, or high-dose psilocybin can be equally or more challenging depending on the individual and context.